Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02234596 · ClinicalTrials.gov registry record · Phase 2
Nintedanib in Patients With Advanced Esophagogastric Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02234596: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02234596 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02234596, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a phase II study of Nintedanib in patients with metastatic or recurrent esophagogastric cancer. The goal of the study is to evaluate the efficacy of Nintedanib, an orally available triple kinase inhibitor targeting the receptors of the vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and fibroblast growth factor (FGF) receptor pathways.
Interventions
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-09-04 |
| Est. Completion | 2020-04-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02234596
The ClinicalTrials.gov registry entry for NCT02234596 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nintedanib is the first listed.
NCT02234596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02234596 about?
NCT02234596 is a clinical study titled "Nintedanib in Patients With Advanced Esophagogastric Cancer". This is a phase II study of Nintedanib in patients with metastatic or recurrent esophagogastric cancer. The goal of the study is to evaluate the efficacy of Nintedanib, an orally available triple kinase inhibitor targeting the receptors of the vascular endothelial growth factor (VEGF), platelet deri...
What is the current status of trial NCT02234596?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2014-09-04. Estimated completion is 2020-04-22.
What interventions are being tested in trial NCT02234596?
The interventions under investigation include: Nintedanib (DRUG).
Who is sponsoring clinical trial NCT02234596?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.